We are grateful for the generous gift of transfected and control Chinese hamster ovary cells from Drs. Marjorie Ariano and David Sibley. We also thank Dr. Carl Lagenaur for his generous assistance with Western blot analysis. This work was supported by a Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD) to S.R.S. and by US. Public Health Service Grants NS08 193 and MH503 14 to S.R.S., EY08055 to C.A., and MH00078, MH40342, and DA04600 to V.M.P. Correspondence should be addressed to Susan R. Sesack The dopamine Dz receptor has been the subject of considerable investigation since its links with mental illness were first suggested (Creese et al., 1976; Seeman, 198 1) . Although additional dopamine receptor subtypes have been discovered and redefined on a molecular basis (Bunzow et al., 1988; Giros et al., 1989; Monsma et al., 1989; Sokoloffet al., 1990; Sunahara et al., 1990 Sunahara et al., , 1991 Zhou et al., 1990; Dearry et al., 1991; Grandy et al., 1991; Van Tol et al., 199 1, 1992) those with greatest homology to the D2 class continue to be implicated in the therapeutic effects of antipsychotic drugs (Sokoloff et al., 1990; Civelli et al., 199 1; Van Tol et al., 1991; Sibley and Monsma, 1992) . The mechanisms through which dopamine systems contribute to normal cognitive and emotive processes, or the pathological disturbances of psychosis, are not yet known. However, a number of important cellular functions have been associated with central Dz receptors, including autoreceptor regulation of dopamine transmission, heteroreceptor regulation of nondopamine transmitter release, and postsynaptic modulation of neuronal excitability and/or protein synthesis (Chesselet, 1984; Mercuri et al., 1985; Young et al., 1986; Lacey et al., 1987; Seeman and Grigoriadis, 1987; Wolf and Roth, 1987; Freedman and Weight, 1988; Drukarch et al., 1989; Williams et al., 1989; Gerfen et al., 199 1) . A more thorough understanding of the sites and mechanisms through which dopamine mediates its crucial modulatory effects can be gained from a comprehensive examination of the neuronal elements and their subcellular components that express dopamine receptors. Studies using in situ hybridization for receptor mRNA have provided a sensitive means for localizing cells that express dopamine receptor subtypes (Mengod et al., 1989; Gerfen et al., 1990; Mansour et al., 1990; Bouthenet et al., 199 et al., 1990) . Ligand-based autoradiography is the method traditionally used to localize available receptors at the light microscopic level (Boyson et al., 1986; Bouthenet et al., 1987; Mansour et al., 1990) . However, autoradiography is sometimes limited in resolution and sensitivity (Lidow et al., 1988) and, furthermore, has proved difficult to adapt to ultrastructural investigations of receptor localization. Although this technique has been carefully applied to electron microscopic localization of peptide receptors (Hamel and Beaudet, 1984; Dana et al., 1989) , interpretation of the results in these studies has depended on the strength of statistical analyses defining the most probable source of autoradiographic signal (Beaudet et al., 1988) . The ligand-based autoradiographic method may also be less useful for revealing the subcellular distribution of receptors prior to insertion in, or following internalization from, the plasma membrane. Moreover, even these limited methods have not yet been applied to the ultrastructural investigation of dopamine receptor expression and localization. Recently, antibodies directed against receptor peptide fragments, or purified receptor proteins, have been successfully employed for immunocytochemical localization of putative catecholamine receptors in the brain (Aoki et al., 1987 (Aoki et al., , 1989 McVittie et al., 1991; Aoki, 1992; Ariano et al., 1993) . The cloning of genes coding for dopamine receptors (Bunzow et al., 1988; Sokoloff et al., 1990; Sunahara et al., 1990, 199 1; Zhou et al., 1990; Dearry et al., 1990; Van To1 et al., 1991) has permitted the production of antisera directed against peptide sequences that have limited homology to other G-protein-linked receptors (cf. McVittie et al., 199 1) . We have produced a polyclonal antiserum in rat directed against a synthetic peptide fragment corresponding to a portion of the third intracellular loop of the dopamine D, receptor (common to both the long and short forms) (Bunzow et al., 1988; Giros et al., 1989; Monsma et al., 1989) . We have utilized this antiserum for a detailed ultrastructural investigation of the cellular and subcellular localization of DZ receptor-like protein in both the midbrain regions that contain dopamine neurons and their postsynaptic targets in the forebrain. The distribution of the receptor peptide has specificity of the D, receptor peptide antiserum. Serial dilutions of unconjugated peptides corresponding to amino acids from the third cytoplasmic loop ofthe D, or p2 adrenergic receptors were blotted onto filter paper, incubated in a 1: 1000 dilution of rat anti-D2-2 antiserum, and processed with the ABC method. The corresponding amino acid sequences are, for p2, 226-239; 02-1, 220-233; 02-2, 213-287; and 02-3, 258-269 (numbers based on the long form of the rat Dz receptor). A dense peroxidase product is seen only against the immunizing D2-2 peptide at concentrations of 25-500 ng. Cross-reaction with the highest con&ration (500 ng) ofthe D2-3 peptide is even less than that seen at 5 ng of the D2-2 peptide.
been further examined in relation to presumed dopamine neurons and processes, using a dual, preembedding immunolabeling method to localize D, peptide and tyrosine hydroxylase (TH), the catecholamine synthetic enzyme, within single sections.
The results of this study have been reported in a preliminary form (Sesack et al., 199 1) .
Materials and Methods Production of polyclonal antiserum
A synthetic peptide fragment corresponding to amino acids 273-287 of the rat dopamine D, receptor sequence (third intracellular loop of the long and short forms) was obtained from Multiple Peptide Systems (San Diego, CA) and conjugated through glutaraldehyde to keyhole limpet hemocyanin (Sigma). The conjugate was dialyzed, homogenized with Freund's adjuvant (Calbiochem), and injected subcutaneously into rats. A total volume of 0.5 ml containing 0.5 mg of peptide was injected. Serum samples were drawn prior to immunization and lo-14 d after each boost injection. Following three or four boosts, animals were deeply anesthetized with sodium pentobarbital and killed by exsanguination. The final serum was stored at -70°C.
Immunoblot and Western blot analysis
For determination ofantibody titer and specificity, immunoblot analysis modified from the method of Larsson (198 1) and standard Western blot techniques were used. For the immunoblot method, immunizing and nonimmunizing peptides from the dopamine D, receptor and the structurally related 0, adrenergic receptor ( Fig. 1) were serially diluted in 0.01 M uhosnhate-buffered saline (PBS). DH 7.4. blotted onto Whatman #l filtef paper, and fixed with parafor'mrddehyde vapors at 60°C for 1 hr. Papers were then rinsed in 0.05 M Tris-buffered saline (TBS), pH 7.6, blocked in 1% bovine serum albumin (BSA) in TBS for 30 min, and then incubated in a 1: 1000 dilution of rat antiserum in 1% BSA-TBS for 1 hr at 37°C. Papers were rinsed in TBS and processed using the avidin-biotin peroxidase (ABC) staining method (Hsu et al., 198 1) . Briefly, papers were incubated in 1: 100 biotinylated donkey anti-rat IgG (Jackson Labs) or 1:400 biotinylated goat anti-rat IgG (Amersham) for 30 min, rinsed, and then incubated in 1: 100 avidin-biotin peroxidase complex (Vector Elite). The bound peroxidase was visualized by reaction with 22 pg of 3,3'-diaminobenzidine (DAB) (Aldrich) and 10 ~1 of 30% I&O, in 100 ml of TBS for 6 min.
For Western blot analysis in three experiments, homogenates of proteins from various brain regions were prepared, run on 7-l 5% gradient polyacrylamide gels, and transferred to nitrocellulose papers (Towbin et al., 1979) . The nitrocellulose papers were incubated for 1 hr at 37°C
Receptor-like lmmunolabeling i n Mi dbrai n and Striatum in dilutions of the rat anti-D1 peptide antiserum ranging from I:500 to 1: 10,000. The bound antibody was visualized using the ABC method as described above. In a fourth experiment, a Western transfer of proteins in enriched membrane fractions (Wu et al., 1986 ) from striatal and cerebellar homogenates was prepared. The concentration of the anti-D, peptide antiserum was increased to 1:250, the incubation was run overnight at room temperature, a secondary goat anti-rat IgG directly conjugated to peroxidase (Cappel; dilution 1:500) was used, and the bound antibody was visualized using 4-chloro-1 -naphthol (Hawkes et al., 1982) as the chromogen for the peroxidase reaction.
Immunocytochemistry
Cultured cells. Chinese hamster ovary (CHO) cells stably transfected with the cDNA for the rat dopamine Dz receptor (McVittie et al., 199 1) were generously donated by Drs. Marjorie Ariano (Chicago Medical School) and David Sibley (NIH-NINDS). The ability of rat polyclonal anti-peptide antiserum to recognize dopamine D, receptor was tested in this cell line. CHO cells grown on coverslips were dehydrated, and then fixed with 4% paraformaldehyde for 10 min, rinsed in PBS, treated with 0.0 1% saponin in PBS three times for 5 min each, and rinsed again. Cells were blocked with I% BSA in 0.1 M TBS and incubated for 18 hr at room temperature, or 42 hr at 4°C in a 1:500 dilution of rat anti-D, peptide antiserum. Untransfected cells were included as controls for nonspecificity of antibody reaction. In addition, transfected cells were incubated in immune serum preadsorbed for 1 hr at room temperature with 100 pg/ml of immunizing peptide. The ABC method described above was used to visualize the bound antibody. Coverslips were then rinsed, dehydrated through graded ethanols, and mounted onto glass slides.
Fixed rat brain tissue. Fifteen male Sprague-Dawley rats (250-300 gm) were anesthetized with pentobarbital, and ofthese, 1 1 were perfused iranscardially with 10 ml of heparin saline (1000 U/ml), followed first bv 50 ml of 3.75% acrolein (Polvsciences). then 2% naraformaldehvde in 0.1 M sodium phosphate buffer, pH 7.4, and then by an additional 200 ml of 2% paraformaldehyde. The remaining rats were perfused either with 4% paraformaldehyde (one animal), 4% paraformaldehyde with 0.2% glutaraldehyde (one animal), or 5% glutaraldehyde (two animals), all in 0. I M phosphate buffer, pH 7.4. Brains were postfixed for 30 min in the final fixative. The composition of fixation solution appeared to exert little effect on the intensity of peroxidase immunoreactivity for the D2 peptide. Thus, the results reported here are primarily from acrolein-fixed tissue.
The brains were sectioned at a thickness of 40 Frn on a vibratome. Sections fixed either with acrolein or 5% glutaraldehyde were treated with 1% sodium borohydride in 0.1 M phosphate buffer (Leranth and Pickel, 1989) . Some vibratome sections were cryoprotected with 25% sucrose and 10% glycerol in 0.05 M phosphate buffer and subjected to a rapid freeze-thaw using liquid Freon, followed by liquid nitrogen. Tissue was then rinsed in phosphate buffer, followed by 0. I M TBS, and blocked for 1 hr in 1% BSA in TBS, to which 0.05% Triton X-100 was added in a few cases. Sections were incubated for 18 hr at room temperature, or 42 hr at 4°C in a 1: 100 to 1:2000 dilution of (I) rat D, peptide antiserum (with or without T&on), (2) preimmune serum, or (3) immune serum to which 100 fig/ml of immunizing peptide had been added. The sections were processed using the ABC method (described above) or double-bridged, peroxidase-antiperoxidase (PAP) staining (Ordronneau et al., 1981) . For PAP labeling, tissue was incubated in I : 100 mouse anti-rat IgG (Accurate) and then 1: 100 rat PAP (Stemberger Meyer), and the steps were repeated. Peroxidase was visualized using DAB as described above. Incubations were performed at room temperature with continuous agitation and sections were rinsed in TBS between incubations.
Dual immunoperoxidase-gold labeling.
In some cases, alternate vibratome sections were dually labeled for (1) D, peptide, using peroxidase immunostaining, and (2) TH, using a preembedding immunogold-silver method . Tissue was co-incubated in a mixture of 1: 1000 rat anti-D, DeDtide and 1:2000 rabbit anti-TH (Job et al.. 1973) . Following DAB n&ion, sections were rinsed in 0.01' M PBS, blocked in 0.8% BSA and 0.1% gelatin in PBS, and incubated for 3 hr in 1:50 goat anti-rabbit IgG conjugated to 1 nm gold particles (Amersham). After rinsing in PBS and 0. I M sodium citrate buffer (pH 7.4), the bound gold was intensified by treatment with silver solution (Amersham) for an empirically determined time (usually 4-7 min).
To control for potential cross-species reaction of secondary antisera, sections incubated separately in either primary antiserum were subsequently treated with the nonmatching secondary IgG species and processed for that marker (i.e., rat anti-l), peptide followed by gold-conjugated anti-rabbit IgG and silver enhancement; or rabbit anti-TH followed by biotinylated anti-rat IgG and ABC processing). In initial studies, the goat anti-rat IgG from Amersham cross-reacted with rabbit anti-TH, producing detectable peroxidase immunoreactivity in substantia nigra and ventral tegmental area perikarya. In the case of biotinylated donkey anti-rat IgG from Jackson Labs, or gold-conjugated goat anti-rabbit antiserum from Amersham, no evidence of species cross-reaction was detectable by light or electron microscopy. Therefore, the results of dual labeling studies presented here derive only from experiments using the latter combination of secondary antisera.
Light and electron microscopy
Singly and dually labeled sections were either slide mounted for light microscopy or further processed for electron microscopic examination. In the latter case, tissue was postfixed in 2% osmium tetroxide in 0.1 M phosphate buffer, dehydrated in ethanol and propylene oxide, and embedded in Epon 8 12 (Leranth and Pickel, 1989) . Ultrathin sections cut from this material were stained with uranyl acetate and lead citrate and examined in a Phillips 201 electron microscope.
Data analysis
Analysis of single labeling for the D2 peptide, and its codistribution with TH immunoreactivity, was confined to the outer l-3 Frn of tissue, where maximal penetration of antibodies and immunological reagents was achieved. Furthermore, in dually stained material, only micrographs containing both peroxidase and gold markers were included for analysis. Quantitative analysis of immunogold particles was not necessary, as specific labeling was considerably greater than background particles in the surrounding neuropil Sesack and Pickel, 1992) .
Definition of neuronal and synaptic elements
The classification of neuronal and synaptic elements in this study followed the descriptions of Peters et al. (1991) . Perikarya were identified as regions of the cell containing the nucleus. Dendrites were defined as processes that exhibited densities postsynaptic to axon terminals. Such processes having diameters greater than 0.7 pm and containing rough endoplasmic reticulum were classified as proximal; dendrites with smaller diameters and fewer ribosomes were considered distal. Dendritic spines, which typically arose from distal processes, were often smaller than dendrites and typically did not exhibit mitochondria, microtubules, or rough endoplasmic reticulum. In some planes of section, a spine apparatus was apparent in the head or neck of the spine. Axon terminals contained numerous synaptic vesicles and measured at least 0.2 Nrn in diameter, while the preterminal portions ofaxons were typically smaller, and contained few vesicles. Asymmetric synapses were identified by their thickened postsynaptic densities, while symmetric synapses had thin densities (Gray, 1959) . Appositions were defined as parallel membrane associations that showed no conventional synaptic morphology, but nevertheless were not separated by astrocytic processes.
Results
Dopamine receptor recognition and antibody specificity By immunoblot analysis, rat antiserum (at 1: 1000 dilution) specifically recognized the immunizing D, peptide with a threshold of 5 ng, but did not cross-react appreciably with other nonimmunizing peptides from adjacent positions on the D, or & adrenergic receptors (Fig. 1) . In cultured CHO cells, the rat anti-D, antiserum produced a dense perinuclear immunolabeling of cells permanently transfected with the cDNA for the D, receptor ( Fig. 2A) , but not untransfected CHO cells (Fig. 2C) . Preadsorption of the immune serum with 100 &ml of D, peptide greatly reduced the intensity of immunoreaction product (Fig.   2B ).
For Western blot analysis, in the three experiments where bound antibody was visualized using the ABC method, no bands . A, In a coronal section through the genu of the corpus callosum (gee), peroxidase D,-LI is diffusely and heterogeneously localized throughout the dorsal and ventral extent of the caudate putamen nucleus (0). D,-LI is also distributed throughout the nucleus accumbens septi (surrounding the anterior commissure, UC) and in the olfactory tubercles.
Peroxidase product can be seen in the cell bridges that connect the latter structures (arrow) . B, In a midbrain section at the level of the commissure of the superior colliculus (csc) and the posterior mammillary nucleus (MP), D,-LI is selectively distributed to the region bounded dorsally by the medial lemniscus (ml) and ventrally by the substantia nigra zona reticulata (SM) . Light immunoreaction product also extends medially into the ventral tegmental area, but does not appear in the lateral aspects of the substantia nigra. Other mesencephalic structures contain only background labeling. Small, darkly staining puncta (small arrows) are blood cells that appeared as well in control sections. Scale bars, 1 mm.
other than those seen in control lanes incubated without primary rum were used, chromogen reaction for 5 min also produced antibody were detected for 1:500-l : 10,000 dilutions of anti-D, no labeled bands. However, between 6 and 20 min of incubation peptide antiserum.
In the remaining experiment, for which in the reaction solution, a weakly labeled band developed in membrane fractions and overnight incubation in 1:250 antiseboth striatal and cerebellar preparations that had an approxi- having the morphological appearance of dendrites. Less numerous, punctate processes are also visible in the neuropil (small solid arrows). B, Within the medial striatum, D,-LI is diffusely and heterogeneously localized within the neuropil, but is absent from myelinated bundles (m). Patches of more intense staining are apparent (large arrow), as are lightly labeled perikarya (small arrows). C, Diffuse D,-LI is localized throughout the neuropil of the dorsolateral striatum, but is absent from the corpus callosum (cc) and myelinated bundles (m). D, Adjacent striatal sections incubated in D, peptide antiserum to which 100 pg/ml of immunizing peptide had been added prior to immunocytochemical processing fail to exhibit detectable immunoreactivity. Arrows indicate dorsal (upward) and lateral (rightward) orientation in the brain. Scale bar, 100 pm. mate molecular weight of 69 kDa (data not shown). This band was not visible in nitrocellulose papers incubated in the absence ofthe primary antiserum. We consider this band to have resulted from nonspecific cross-reaction of the antiserum under the excessive labeling conditions used in this experiment. In contrast, adjacent lanes run in parallel showed bands strongly immunoreactive for a neural cell adhesion molecule (Chung et al., 199 1) within 1 min of incubation in chromogen.
Light microscopic localization of D,-LI Diffuse peroxidase product for D, receptor-like immunoreactivity (D,-LI) was specifically localized in basal ganglia structures, including forebrain striatal regions and the midbrain ventral tegmentum (Fig. 3) . Immunolabeling was not visible in the neocortex, diencephalon, caudal brainstem, or cerebellum. Immunolabeled perikarya were detected in the substantia nigra zona compacta and in the ventral tegmental area (Figs. 3B, 4A) . Thick, nonvaricose processes (most likely dendrites) emanating from these cells were also detected within these areas, and in the substantia nigra zona reticulata. Other mesencephalic regions examined in the same sections exhibited little or no detectable D2-LI (Fig. 3B) . In forebrain areas, D,-LI was localized to diffusely distributed punctate processes throughout the dorsal and ventral aspects of the caudate putamen nucleus (striatum), as well as the nucleus accumbens and olfactory tubercles (Fig.  3A) . Peroxidase immunoreactivity was not readily detectable in cortical regions by light microscopy (Fig. 3A) . Within the striaturn, D2-LI was heterogeneously distributed within the neuropil (Fig. 4B,C) , with patches of dense immunoreactivity surrounded by areas of lighter labeling (Fig. 4B) . A few perikarya were lightly labeled (Fig. 4B) . No peroxidase product was detected within the striatal white matter or corpus callosum (Figs. 3A,  4B, C) .
When midbrain or forebrain sections were incubated in preimmune serum (not shown) or rat immune serum preadsorbed with the immunizing D, peptide (Fig. 40) , no peroxidase labeling was detected. Immune serum preadsorbed with nonimmunizing peptides from the D, or 6, adrenergic receptors produced specific labeling of the midbrain and striatum comparable to that seen with immune serum alone (not shown).
Electron microscopic cellular and subcellular localization of D,-LI: correlation to TH immunoreactivity Substantia nigra/ventral tegmental area Within a region encompassing the medial substantia nigra and the paranigral ventral tegmental area, diffuse and light labeling for D,-LI was seen in perikarya at the electron microscopic level. In these perikarya, the Golgi apparatus and rough endoplasmic reticulum typically lacked detectable D,-LI (not shown). More intense peroxidase product was seen in the dendritic branches of these cells in tissue either singly labeled for D,-LI (Fig. 5) or dually labeled for Dz peptide and TH (Fig. 6) . Within dendrites, D2-LI was most intensely localized to saccules of smooth endoplasmic reticulum and to patches along plasmalemmal surfaces postsynaptic to axon terminals (Fig. 5B) . Less intense Dz-LI was distributed along nonsynaptic portions of the plasmalemma1 surface and in association with microtubules and mitochondrial membranes. Neither myelinated axons nor axon terminals exhibiting D2-LI were seen in this region. However, small intensely labeled, presumably axonal processes were often observed in bundles of unmyelinated axons (Fig. 54) . Occasionally, in a favorable plane of section such as seen in Figure  6B , peroxidase labeling could be seen in preterminal portions of axons whose terminal varicosities were devoid of immunoreactivity. Weak D,-LI was also occasionally localized to astrocytic processes in apposition to immunolabeled dendrites (Fig.  6) .
In dually labeled sections through the substantia nigra and ventral tegmental area, numerous dendrites contained both peroxidase immunoreactivity for the D2 peptide and gold-silver immunolabeling for TH (Fig. 6.4) . Within the same sections, other dendrites were singly labeled for either D,-LI or TH immunoreactivity. These singly labeled dendrites were frequently observed in close proximity to one another (Fig. 6B) . Goldsilver particles were localized throughout the cytoplasm of THimmunoreactive dendrites and were rarely detected in the sur- Figure 5 . Electron micrographs of D,-LI in the medial substantia nigralventral tegmental area. A, At low magnification, numerous dendrites exhibit peroxidase D2-LI (02-O). Other unlabeled dendrites exhibit no detectable immunoperoxidase reaction product (uD). Small, intensely labeled processes are seen in the neuropil (arrows), often adjacent to other nonimmunoreactive myelinated (MA) and unmyelinated (uA) axons. B, At high magnification, D2-LI within dendrites is prominently localized to saccules of smooth endoplasmic reticulum (ser) and along the outer membranes of certain mitochondria (m). D,-LI is also localized to the densities postsynaptic to unlabeled axon terminals (UT) (curved arrows). Nonsynaptic portions of the plasmalemmal surface also show accumulations of immunoreaction product (straight arrows). Scale bars: A, 0.5 Km; B, 0.25 Frn. proximal dendrite, but is highly localized to more distal aspects of the same process. A patchy distribution of D,-LI is localized to plasmalemmal surfaces that are apposed to an unlabeled axon (uA) (straight arrow) and to another immunoreactive dendrite (facing arrowheads). Note the absence of peroxidase product at plasmalemmal surfaces in contact with unlabeled terminals (curvedarrows). In more distal portions of the dendrite, D,-LI is most intensely associated with smooth endoplasmic reticulum (ser) and microtubules (mt). B, Dense peroxidase D,-LI is detected within distal dendrites, particularly in association with the smooth endoplasmic reticulum (ser) and spines (s). Unlabeled spines (US) and dendrites (uD) are visible in the surrounding neuropil. The immunolabeled dendrites exhibit close membrane appositions with labeled and unlabeled dendrites (facing arrowheads). C, Within spines, peroxidase reaction product for D,-LI is densely associated with the spine apparatus (su) and densities postsynaptic to unlabeled axon terminals (UT) (curved arrows). The postsynaptic density at the fop of the micrograph appears more intensely labeled than that in the lower right. Scale bars: A, 0.5 pm; B and C, 0.25 pm.
rounding neuropil. The subcellular distribution of D,-LI did not differ from that observed in singly labeled tissue.
Striatum
The cellular and subcellular distribution of D,-LI within medial and dorsolateral regions of the striatum resembled that seen in the midbrain.
Dendrites were the most intensely immunoreactive neuronal elements, exhibiting dense peroxidase product in association with smooth endoplasmic reticulum, some microtubules, and plasmalemmal surfaces, particularly in regions of synaptic specializations (Fig. 7) . The greatest density of D,-LI was detected at distal portions of the dendritic tree, with maximal labeling occurring in dendritic spines (Fig. 7) . The spine apparatus, when visible within the plane of section, was usually associated with dense D,-LI (Fig. 7C) . Immunoreactive dendrites often exhibited close membrane appositions with other dendrites that either contained or lacked D,-LI (Fig. 7B) .
The subcellular distribution of D,-LI within axons was heterogeneous, with peroxidase product densely localized along the plasmalemmal surface of unmyelinated axons (Fig. 84) , some of which were continuous with vesicle-filled varicosities (Fig.  SD) . Furthermore, D,-LI was localized to some, but not all synaptic vesicles, and these were frequently located near one plasmalemmal surface (Fig. 8 ). These D, peptide-labeled terminals were only seen near the surface of the tissue. D,-LI was rarely detected in myelinated axons.
The majority of D, peptide-labeled terminals were small and lacked detectable synaptic junctions in the single sections analyzed. However, some terminals exhibiting D,-LI formed punctate symmetric synapses with distal dendrites or the necks of spines (Fig. 84,C) . These synapses were identified by their parallel apposed, electron-dense membranes and intercleft filaments. Postsynaptic densities were either thin or absent at these junctions.
In a few instances, terminals forming asymmetric synapses with spines showed detectable D,-LI (Fig. 8B) . The dendritic targets of D, peptide-immunoreactive terminals were typically unlabeled, although a few exhibited D,-LI (Fig. 8C) .
In striatal sections, gold-silver immunoreactivity for TH was localized exclusively to axon terminals, the majority of which did not contain peroxidase labeling for D,-LI (Figs. 8C, 9 ) and lacked recognizable junctions in single sections (Figs. SC,D; 9) . Occasionally, terminals contained immunoreactivity for both TH and D, peptide (Fig. 8D) ; these also were typically nonjunctional when viewed in single sections. TH-immunoreactive terminals sometimes contacted dendritic targets containing detectable D,-LI. In most cases, the targets were the heads or necks of spines (Fig. 9) . Classically defined synaptic junctions were usually not observed between these elements when viewed in single or a limited number of serial sections. Close membrane appositions were also observed between TH-immunoreactive terminals and the unlabeled terminals forming asymmetric synapses on D, peptide-immunoreactive spines (Fig. 9C ).
Discussion D,-LI was intensely localized to (1) brain regions containing dopamine neurons and their processes; (2) plasmalemmal surfaces and organelles of proximal and distal dendrites, unmyelinated axons, and axon terminals; (3) midbrain and striatal processes that colocalized TH, or were postsynaptic to THimmunoreactive axon terminals; and (4) dendrites in the ventral midbrain and striatal axon terminals that exhibited no detectable TH-labeling.
These multiple locations of the D, receptor peptide, and their relation to TH-immunoreactive processes, is shown diagrammatically in Figure 10 . The immunocytochemical electron microscopic localization of a D, receptor-like protein provides a sensitive means for determining the potential cellular and subcellular elements expressing these proteins in dopamine pathways.
Antiserum specificity
Several lines of evidence suggest that the immunoreactive species presently identified by anti-peptide antiserum in fixed tissue may be the dopamine D, receptor. (1) The selective immunolabeling of cultured CHO cells permanently transfected with the cDNA for the rat dopamine D, receptor, but not untransfected cells, suggests that the dopamine D, receptor was specifically recognized. The reduction of immunostaining by peptide preadsorption also supports specificity of the antibody for the immunizing DZ peptide sequence. (2) The direct correlation between the light microscopic distribution of D,-LI in fixed rat brain tissue and both autoradiographic detection of D, receptors (Boyson et al., 1986; Bouthenet et al., 1987; Mansour et al., 1990) and immunocytochemical localization of receptors using other anti-peptide antisera (Ariano et al., 1993) In order to acknowledge that other proteins structurally similar to the D, receptor peptide might additionally be recognized, the antigenic species immunolabeled by anti-peptide antiserum in fixed brain tissue is herein referred to as a "DZ receptor-like" protein. In this regard, Western blot analysis of brain homogenates using the anti-D, peptide antiserum failed to label proteins in the molecular weight range (Amlaiky and Caron, 1986) of the D, receptor. In one instance, the anti-D, peptide antiserum did weakly label a 69 kDa protein in striatal and cerebellar membrane fractions. We believe that this staining, which was seen in only one of four experiments, represents nonspecific labeling resulting from the excessive antibody concentrations and incubation conditions used in this experiment. Furthermore, we do not believe that this protein is labeled immunocytochemically in fixed tissue, as comparable antibody dilutions were never used for these studies, and peroxidase product was never detected within the cerebellum. Thus, the anti-D, peptide antiserum appears to label an antigen in fixed tissue that is below threshold for recognition by the Western blot assay. This difference may reflect both the low levels of total tissue protein contributed by the dopamine D, receptor (Strange, 1990 ) and the preferential recognition by the antiserum of a fixed form of the antigen.
Additional studies will be needed to assess whether the D, peptide antiserum cross-reacts with other dopamine receptor subtypes. However, the present results suggest that such crossreactivity is unlikely. First, amino acid sequences homologous to the D, peptide fragment used for immunization do not occur in the published sequences of D,,, D,, (D,), D,, or D, receptors (Civelli et al., 1991; Sibley and Monsma, 1992) . Second, immunoperoxidase product was not detected in axon terminals in the substantia nigra/ventral tegmental area, the major site of D, receptor localization in this region (Mansour et al., 1990; Fremeau et al., 199 1; Meador-Woodruff et al., 199 1; Weiner et al., 199 1; Huang et al., 1992) . Third, an increasing dorsal to ventral density of immunoreactivity in forebrain targets was not observed, as would be expected if this antiserum also recognized D, receptors confined to limbic structures (Sokoloff et al., 1990; Bouthenet et al., 199 1) . Finally, peroxidase immunoreactivity did not exhibit greater density in cortex, compared to striatum, as has been reported from Northern blot analysis of D, receptor probe (Van To1 et al., 199 1) .
Light microscopic immunocytochemical localization The localization of D, peptide-immunolabeled perikarya in the zona compacta of the substantia nigra and the ventral tegmental area, as well as the distribution of immunoreactive processes throughout the dorsal and ventral extent of the striatum, matches the regions of heaviest immunolabeling seen with other anti-D, peptide antisera (Ariano et al., 1993) and furthermore, corresponds to the distribution of immunolabeling for TH or dopamine (Pickel et al., 197.5; Geffard et al., 1984; Decavel et al., 1987) . The present observations also agree in essence with the results of autoradiographic studies describing the localization of dopamine receptor ligands (Boyson et al., 1986 ; Bouthec Figure 10 . Schematic diagram illustrating the cellular localization of immunoreactivities for the dopamine D, receptor peptide and TH in the midbrain and striatum. The distribution of D,-LI is represented by graded shading, and TH localization is shown by hatching. All other processes were not identified in terms of their receptor or transmitter content and are unlabeled (UL). Many dendrites in the substantia nigra and ventral tegmental area (SN/vTA) exhibit both D, receptor peptide and TH labeling, although some dendrites contain only one of these markers. Perikarya and the most proximal dendrites typically contain only low levels of D,-LI. In the striatum, the greatest density of D,-LI occurs in spines (inset) and distal dendritic processes, with considerably lighter labeling evident in more proximal processes and perikarya. Only a population of spines and dendrites in the striatum exhibit detectable D,-LI. Some of these labeled processes are contacted by terminals containing immunoreactivity for TH. A heterogeneous distribution of D,-LI is also detectable in the preterminal and varicose portions of axon terminals. Most of these terminals make thin, symmetric synapses on spines or distal dendrites, or fail to form synaptic junctions in single planes of section. A few D, peptide-immunoreactive terminals are identified as catecholaminergic (presumably dopaminergic) on the basis of their TH immunoreactivity (inset). Other unmyelinated axons (not shown) and terminal varicosities without TH immunoreactivity also contain D,-LI. Some of these labeled terminals from asymmetric axospinous synapses, while others, like the TH axons, primarily contact the necks of spines (inset). net et al., 1987; Mansour et al., 1990 ) although a systematic comparison of all brain regions was not attempted. The limited light microscopic immunolabeling of cortex by the D, peptide antiserum may reflect the low level of D, receptor expressed in cortical tissue (Bouthenet et al., 1987 (Bouthenet et al., , 1991 Mansour et al., 1990; Weiner et al., 1991) . However, D,-LI was detectable by electron microscopy in the prefrontal cortex (S. R. Sesack and V. M. Pickel, unpublished observations), which is densely innervated by dopamine fibers (Van Eden et al., 1987) . Thus, while immunocytochemical localization of D, peptide at the light microscopic level may be less sensitive than autoradiographic methods, it appears to be suitable for electron microscopic localization. Ultrastructural localization of D,-LI Subcellular distribution Heterogeneities in the density of subcellular D, peptide labeling suggest that there is some selectivity of organelle-and membrane-associated peroxidase product. For example, not all vacuoles of smooth endoplasmic reticulum, synaptic vesicle membranes, or regions of plasmalemmal surface exhibited D, peptide labeling in otherwise immunoreactive processes. Thus, the presence of antigen may not be uniform in these structures. The observation of immunolabeling primarily on the intracellular membrane surface, and not within the synaptic cleft or extracellular space, is consistent with detection of an intracellular protein, or an intracellular loop of an integral membrane protein (Aoki et al., 1989) . The present description of subcellular localization of D,-LI may be complicated, to some degree, by the diffusibility of peroxidase reaction product (Novikoff et al., 1972) . Future studies using less diffusible immunogold techniques will be needed to verify the present results and to characterize further the loci of antigen in transit or inserted into the plasma membrane.
Substantia n&a/ventral tegmental area In the medial substantia nigra and ventral tegmental area, the localization of dense immunolabeling in dendrites, and not axon terminals, is consistent with the localization of D, peptide in dopamine neurons that possess few recurrent collaterals (Bayer and Pickel, 1990) . As mentioned previously, these results also suggest that the D, peptide antiserum does not recognize D, receptors that have been shown to reside on axons and terminals (Huang et al., 1992) , presumably descending from the striatum and ventral forebrain (Mansour et al., 1990; Fremeau et al., 1991; Meador-Woodruff et al., 1991; Weiner et al., 1991) . The finding that D,-LI was intensely localized to small processes that were frequently surrounded by other unmyelinated axons suggests that extrinsically or intrinsically directed axons may express a D, receptor-like protein. Sparse peroxidase product for D, peptide in astrocytic processes also is consistent with the localization of dopamine receptors, which have been described on astroglial cells (Murphy and Pearce, 1987; Hansson and RGnnback, 1988) .
Perikarya and large proximal dendrites exhibited only weakly detectable D,-LI, even at the tissue surface where antibody penetration was maximal. This finding implies that the antigen recognized by the D, peptide antiserum reaches detectable levels only in more distal portions of dendrites, and/or is detectable only at a late posttranslational stage. The latter suggestion is consistent with the subcellular distribution of D,-LI to the smooth endoplasmic reticulum, and not the rough endoplasmic reticulum or the Golgi apparatus. The labeled saccules of smooth endoplasmic reticulum also may reflect internalized receptor from the plasmalemmal surface (Broadwell et al., 1980; Holtzman, 1992) .
The observation that numerous D, peptide-immunoreactive dendrites in the midbrain also contained immunogold labeling for TH, an exclusive marker for dopamine neurons in this region (Swanson and Hartman, 1975) clearly demonstrates that the DZ peptide antiserum recognizes an antigen contained in the dopaminergic cell group. This finding is consistent with the localization of a D, autoreceptor, which dopamine neurons have been shown to express on the basis of physiological, biochemical, and anatomical evidence (Aghajanian and Bunney, 1977; Skirboll et al., 1979; White and Wang, 1984a; Lacey et al., 1987; Wolf and Roth, 1987; Morelli et al., 1988; Le Moine and Bloch, 199 1) . In some instances, TH-labeled dendrites did not contain detectable D,-LI, consistent with reports that some dopamine neurons are devoid of, or express only low levels of, D, receptors (Chiodo et al., 1984; White and Wang, 1984b; Le Moine and Bloch, 199 1) . Alternatively, subpopulations of dopamine neurons may express D, (Sokoloff et al., 1990; Bouthenet et al., 1991) or some other, as yet uncharacterized, variant of D, receptors.
Occasionally, dendrites in the substantia nigra/ventral tegmental area contained D,-LI but lacked immunogold reaction product for TH. Frequently these dendrites were immediately adjacent to processes exhibiting intense TH immunoreactivity. One explanation for this finding is that the D, peptide may be expressed in some nondopamine neurons, consistent with physiological accounts of dopamine's local effects in the midbrain (Ruffieux and Schultz, 1980; Cheramy et al., 198 1; Waszczak and Walters, 1986) . Alternatively, these dendrites may arise from neurons reported to express high levels of D, mRNA, but low levels ofTH immunoreactivity (Le Moine and Bloch, 199 1).
Before alternative explanations for D, peptide localization can be further explored, limitations in the sensitivity of dual labeling immunocytochemical methods must be considered. To some extent, an underestimation of dually labeled dendrites may have resulted from inequivalent sensitivities of the immunoperoxidase and immunogold methods . In addition, we have noted that some loss of label occurs with combined primary antibody incubation, compared to single antibody labeling at the same dilution (Sesack and Pickel, unpublished observations) . Finally, the ability to detect low levels of peroxidase reaction product may also be limited by heavy metal staining. In this regard, initial studies with unstained tissue from the midbrain indicate that D,-LI is detectable in most THlabeled dendrites. Future studies directed toward a more quantitative assessment of the codistribution of D, peptide and TH are in progress. Striatum Dendrites. In the medial and dorsolateral aspects ofthe striatum, the predominant localization of D,-LI to spines and distal dendrites matches the preferential distribution of synapses formed by dopamine terminals on the most distal portions of medium spiny neurons (Bouyer et al., 1984; Freund et al., 1984) . These findings further suggest that the antigen recognized by the D, peptide antiserum may reflect receptive sites for dopamine, although the distribution of dopamine receptors may not always parallel dopamine synaptic inputs. The observation that numerous dendritic processes in the striatum contained no detectable D,-LI may be consistent with the segregation of dopamine receptor subtypes to different populations of striatal neurons (Gerfen et al., 1990) . Alternatively, a restricted localization of D, peptide immunoreactivity to the necks of some spines also would give the impression of nonlabeling whenever continuity between spines and dendrites was not seen within the plane of section. Since some striatal cells may express multiple dopamine receptor classes (Meador-Woodruff et al., 199 1; Surmeier et al., 1992) future dual labeling immunocytochemical (and/or in situ hybridization) studies are needed to examine further the cellular and subcellular expression of multiple receptive sites for dopamine.
The potential functional significance, if any, of D,-LI at sites of plasmalemmal apposition between striatal dendrites is not known. However, it is interesting to note that electrical and dyecoupling of cells in striatum have been described in physiological studies (Cepeda et al., 1989) and that dopamine appears to reduce the resistance of these presumed intercellular channels through a D, receptor action (Onn et al., 1992) . Axons and axon terminals. The predominant features of striatal axons and terminals containing D,-LI are similar to those described for dopamine axons: lack of appreciable axon myelination, small size of varicosities, content of primarily small chemical evidence favoring D, receptor regulation ofexcitability and glutamate release from these terminals (Mercuri et al., 1985; Kornhuber and Kornhuber, 1986; Yang and Mogenson, 1986; Maura et al., 1988; Garcia-Munoz et al., 1991) . Our findings are supported by similar ultrastructural observations with other D, peptide antibodies (M. A. Ariano, personal communication) and agree with radioligand binding studies reporting difficulty in detecting appreciable D, receptor distribution on corticostriatal terminals (Trugman et al., 1986; Joyce and Marshall, 1987) . The heterogeneous localization of immunoreactivity for clear vesicles, frequent nonjunctional contacts in single sections, the DZ peptide within these terminals may account for the inand occasional formation of thin, symmetric synapses on spines frequent detection in single planes of section. Furthermore, the and distal dendrites (Bouyer et al., 1984; Freund et al., 1984) .
observation of D,-LI in numerous unmyelinated, non-TH-laThe dopaminergic nature of some D, peptide-immunoreactive beled axons suggests that functional sites for dopamine reception varicosities was further suggested by their colocalization of TH, may reside along preterminal portions of axons at a distance which is primarily contained in dopamine, as opposed to norfrom the synaptic specialization. Alternatively, terminals meepinephrine, terminals in this region (Swanson and Hartman, diating an excitatory, presumably glutamatergic, postsynaptic 1975) . However, our dual labeling studies suggest that the variaction may express an as yet unidentified variant of dopamine case portion of most TH-labeled terminals contained little, if receptors. The resolution of this controversy may depend upon any, D,-LI, having instead a more restricted distribution of further refinements of receptor characterization or anatomical receptors on preterminal axons. Thus, our results are consistent localization methods. with the ultrastructural localization of dopamine nerve terminal autoreceptors (Wolf and Roth, 1987) but suggest a more discrete Conclusions and implications for future studies localization than previously appreciated. However, given the The light and electron microscopic distribution of D,-LI is conlimitations of the dual labeling method outlined in the previous sistent with the localization of a dopamine D, receptor-like section, it must also be considered that the codistribution of D, protein. This antigen is contained in both dopamine (TH-conpeptide and TH immunolabeling was underestimated in the taining) and nondopamine midbrain neurons, suggesting that present study.
dendritically released dopamine in this region may have physOur findings are also consistent with the presence of a D, iological actions on nondopamine cells, in addition to its proreceptor-like protein on nondopamine axon terminals having posed role in autoreceptor regulation of dopamine neuron exmorphological characteristics that are similar to dopamine varcitability. The finding that not all TH-immunoreactive cells icosities. For example, striatal cholinergic interneurons express express readily detectable D,-LI is consistent with a low level mRNA for dopamine D, receptors (Le Moine et al., 1990) , and of autoreceptor expression in some dopamine neurons, making these receptors appear to regulate ACh release (Fujiwara et al., dopamine cell groups heterogeneous with regard to autoreceptor 1987; Wedzony et al., 1988; Drukarch et al., 1989) . Furtherregulation. more, terminals immunoreactive for the synthetic enzyme choIn striatal tissue, the expression of D, peptide by only a popline acetyltransferase (ChAT) have been observed (Pickel and ulation of spines and dendrites is consistent with at least partial to form axonal and dendritic associations similar segregation of D, and D, receptors to separate striatal neurons. to those presently described for D, peptide-immunoreactive
The localization of D, peptide to nonjunctional axon terminals varicosities. However, as yet, there is no convincing evidence that also contain immunoreactivity for TH, or to those forming for direct synaptic input from dopamine terminals onto cholinprimarily symmetric synapses on spines or distal dendrites, sugergic cells or onto any class of terminals gests that many presynaptic D, receptors in the striatum repin the striatum (cf. Bouyer et al., 1984; Freund et al., 1984;  resent dopamine autoreceptors. However, the possibility re- Pickel and Chan, 1990; Sesack and Pickel, 1992) . Thus, if D, mains that some presynaptic D,-LI represents heteroreceptors receptors are indeed present on axons (and/or dendrites) of chofor dopamine on nondopamine terminals, supporting pharlinergic interneurons, they may be functionally activated by macological evidence for dopamine-mediated regulation of dopamine diffusing from terminal release sites (Wightman and transmitter release in this brain region. Future ultrastructural Zimmerman, 1990) . Additional dual labeling studies will be studies localizing dopamine receptor peptides, neurotransmitneeded to determine whether some D, peptide-immunoreactive ters, and neuronal tract-tracing agents are needed to clarify furterminals derive from aspiny cholinergic interneurons, from ther the functional significance of receptor localization for mechGABAergic projection neurons (Girault et al., 1986) or from extrinsic afferent sources (Chesselet, 1984) .
The present results also show D, receptor peptide localization on a few terminals forming asymmetric synapses on spines, particularly in tissue pretreated by rapid freeze-thaw to enhance antibody penetration. Thus, our results are consistent with the localization of D, heteroreceptors on the class of corticostriatal and thalamostriatal terminals forming asymmetric axospinous synapses (Bouyer et al., 1984; Freund et al., 1984; Dube et al., 1988) . However, the infrequent detection of immunoreactivity in this terminal class, or in heavily myelinated axons, cannot presently account for the magnitude of physiological and bio- 
